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Abstract
Background: Urease B is an important virulence factor that is required for Helicobacter pylori to colonise the gastric
mucosa. Mouse monoclonal antibodies (mAbs) that inhibit urease B enzymatic activity will be useful as vaccines for
the prevention and treatment of H. pylori infection. Here, we produced murine mAbs against urease B that
neutralize the enzyme’s activity. We mapped their epitopes by phage display libraries and investigated the
immunogenicity of the selected mimotopes in vivo.
Results: The urease B gene was obtained (GenBank accession No. DQ141576) and the recombinant pGEX-4T-1/
UreaseB protein was expressed in Escherichia coli as a 92-kDa recombinant fusion protein with glutathione-S-
transferase (GST). Five mAbs U001-U005 were produced by a hybridoma-based technique with urease B-GST as an
immunogen. Only U001 could inhibit urease B enzymatic activity. Immunoscreening via phage display libraries
revealed two different mimotopes of urease B protein; EXXXHDM from ph.D.12-library and EXXXHSM from ph.D.
C7C that matched the urease B proteins at 347-353 aa. The antiserum induced by selected phage clones clearly
recognised the urease B protein and inhibited its enzymatic activity, which indicated that the phagotope-induced
immune responses were antigen specific.
Conclusions: The present work demonstrated that phage-displayed mimotopes were accessible to the mouse
immune system and triggered a humoral response. The urease B mimotope could provide a novel and promising
approach for the development of a vaccine for the diagnosis and treatment of H. pylori infection.
Background
Helicobacter pylori is a helical Gram-negative bacillus
that was originally discovered by Marshall and Warren
in the stomach of patients with gastritis and peptic
ulceration [1]. H. pylori has subsequently been recog-
nised as the major aetiological determinant of various
gastroduodenal diseases. Approximately half of the
world’s population has been estimated to be infected by
H. pylori and harbours the bacterium in their upper
gastrointestinal tract [2]. Even though antibiotic-based
triple therapy is still the most effective treatment for
H. pylori infection, it seems that it is not feasible for
large-scale control of infection, partly because of the
high cost, poor compliance, and emergence of antibio-
tic-resistant strains. Increasing rates of therapeutic treat-
ment failure and high rates of re-infection, together with
low hygiene standards in developing countries have
made it imperative to develop vaccines to control infec-
tion [3].
Currently, most H. pylori vaccines in animal models
have utilised whole-cell preparation of native or recom-
binant proteins from the bacterium, together with
mucosal adjuvant. In general, these vaccines are
designed from a natural form of the pathogen after lysis
or inactivation that differs from natural epitopes [4]. In
response to H. pylori infection, the host triggers
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Although H. pylori-specific antibodies have been
detected at high titres in inflamed gastric mucosa and in
the serum, the infection can persist and/or never
resolve. This suggests that H. pylori can evade the innate
and adaptive immune responses, and the latter
responses triggered by H. pylori via this natural
approach do not elicit effective immunity [5]. Therefore,
we hypothesise that modified immunity might be
achieved via the use of mimotopes that differ from nat-
ural epitopes. This approach might be able to trigger an
effective immune response that is absent in natural
infections and natural-immunity-based approaches.
Phage display peptide libraries are usually employed to
select epitopes, which mimic the epitopes of natural
proteins recognised by the immune system. Such mimo-
topes are widely used in the development of vaccines
against many diseases [6-8], the design of molecules that
act as agonists or antagonists to many key biomolecules,
and the development of diagnostic reagents [9-12]. It
has been reported that mimotopes induce production of
protective antibodies, and consequently, become candi-
dates for the development of potential vaccines [13,14].
Mimotopes selected from random peptide libraries can
drive an active immune response towards the original
antigen and lead to effective immunity [15-17].
Urease plays a central role in the pathogenesis of
H. pylori infection and promotes colonisation of the sto-
mach and gut. Urease enzymatically hydrolyses urea to
form ammonia and bicarbonate, which neutralise gastro-
intestinal acids and protect the bacteria against the
acidic environment of the stomach. Urease is composed
of two major subunits, urease A and urease B, and the
latter is considered to be an excellent antigen for the
induction of protective immune responses [18,19].
Mucosal vaccination with Lactococcus lactis that
expresses urease B induces the production of IgG in
blood and urease-B-specific faecal IgA against H. pylori
infection [20]. Recently, by transformation of the gene
of urease B into carrot, Zhang et al. have found that
transgenic carrot plants can express the protein of
urease B and effectively induce immune responses in
mice [21]. In addition, immunisation of mice with the
trivalent fusion vaccine that was constructed by geneti-
cally linking heat shock protein A (HspA), H. pylori
adhesion (HpaA) and urease B414 (250-387 aa), has
been shown to protect mice from H. pylori infection
[22]. Thus, urease B appears to be an important target
for the design of a prophylactic vaccine for H. pylori.
Using this technique, we have already obtained the
neutralising mimotopes of Lpp20 and catalase for
H. pylori [23,24]. Whether such mimotopes of urease B
can be exploited to elicit functional antibody responses
against H. pylori has yet to be fully investigated.
In the present study, we applied the phage display
technology to identify the neutralising epitope of
H. pylori urease B with specific monoclonal antibody
(mAb) U001 that has been shown to inhibit significantly
urease activity. Two phage-displayed libraries were
immunoscreened and the selected phage clones were
analysed. The mimotopes were used to immunise
BALB/c mice and the immune responses for the phago-
topes were evaluated.
Results
Expression and purification of recombinant protein
Genomic DNA extracted from H. pylori was used as a
template for PCR. To amplify the DNA that encoded
urease B, which included a major part of the active site,
primers were designed as described in the Methods. An
aliquot of the PCR mixture was analysed by agarose gel
electrophoresis and a DNA fragment of about 1700 bp
was detected, which corresponded to the expected posi-
tion of urease B. The DNA sequence was submitted to
GenBank (accession No. DQ141576). Expression of
recombinant protein urease B-GST was harvested from
Escherichia coli (Top10) and analysed by SDS-PAGE.
We observed a band of 92 kDa, which corresponded to
the predicted molecular size of the fusion protein
(Figure 1). Soluble urease B-GST protein was purified
by glutathione Sepharose (Figure 2) and used as the
immunogen. Western blotting confirmed that sera from
an H. pylori-infected patient specifically recognised the
recombinant urease B protein, whereas the negative sera
could not (Figure 2).
Production and characterisation of anti-urease B mAbs
Five hybridomas, U001-U005, were obtained by cell
fusion. All mAbs were IgG1 () and showed high speci-
ficity to urease B. The titre of culture supernatant and
ascites fluid was 1:32-1:64 and 1:32,000-1:128,000,
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Figure 1 SDS-PAGE analysis of expression of pGEX-4T-1/urease
Bi nE. coli. 1: pGEX-4T-1 before induction; 2: pGEX-4T-1 after
induction; 3: pGEX-4T-1/urease B before induction; 4: pGEX-4T-1/
urease B after induction; 5: protein marker.
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Page 2 of 12respectively. Triple serial concentrations of the antigen
and each mAb were selected to construct the corre-
sponding curves and to extrapolate the Kaff values using
the formula given in the Methods section. The apparent
Ka values for the five mAbs varied from 1×10
8/M to
1×10
12/M. mAb U001 displayed the highest affinity of
~10
12/M (data not shown).
Inhibition and competition studies using increasing
concentrations of inhibitor or competitor mAbs revealed
that four of the five mAbs (U001, U003, U004 and
U005) competed significantly with each other, which
indicated recognition of the same or overlapping epi-
topes. However, U002 did not compete with the other
antibodies and recognised a distinct epitope.
Urease B enzymatic activity was measured and the
inhibitory effects of U001 and U002 were quantitated by
means of an inhibition assay. The inhibition rates were
calculated by comparing mAb-treated and control rates
for Urease B activity (Figure 3). U001 possessed the
strongest inhibitory effect on urease B enzymatic activ-
ity, whereas mAb U002 had a very moderate effect.
Screening of phage display peptide libraries and
characterisation of recombinant phage
To map the neutralising epitopes of urease B that were
recognised by mAb U001, the Ph.D.-12 and Ph.D.-C7C
libraries were screened with this purified mAb. After three
rounds of biopanning, the ratio of output/input increased
(Table 1) and 70 clones (35 each from the Ph.D.-12 and
Ph.D.-C7C libraries) were randomly selected. When tested
by ELISA for their immunoreactivity with mAb U001, 29
dodecapeptide clones and 28 heptapeptide clones gave
positive signals (Figures 4 and 5) with BSA cross-reactivity,
and sequences of 15 clones for each library were tested.
The deduced amino acid sequences of the corresponding
inserts were identified as six different sequences for
the Ph.D.-12 library and five for the Ph.D.-C7C library
(Table 2). The deduced amino acid sequences of selected
phage clones were aligned and analysed. The amino acid
sequences appearing in more than three different selected
clones and matched with urease B protein were grouped
as the consensus residues and +summarised with bold
letters (Table 2). Although these clones did not match the
urease B protein sequence, they shared extensive homol-
ogy with each other and were clustered and classified as
the conformational epitopes of urease B. Peptide
EXXXHDM from the Ph.D.-12 library and EXXXHSM
from the Ph.D.-C7C library showed a good match with the
urease B protein at 347-353 aa. Amino acids E, D, H, M
and S are key residues of the urease B epitope.
Competitive ELISA was performed to confirm the spe-
cificity of the positive clones. The results showed that the
recombinant phage D1 clone (with EHWSHDMFSPGD
sequence) and phage H1 clone (with EKLKHSM
sequence) all inhibited the mAb U001 binding to recom-
binant urease B protein, whereas wild-type M13 phage
had no effect (Figure 6).
Immune response induced by the selected phage clones
To evaluate the immune responses induced by the
selected mimotopes as vaccine candidates, phage clones
AB C
Figure 2 SDS-PAGE analysis of purified urease B and Western
blot analysis of urease B reactivity with patient serum.
(A) Bacteria expressing GST-urease B were lysed by sonication, and
the supernatant was applied to a Glutathione Sepharose 4B column.
Purified urease B was analysed on a 10% SDS-PAGE. 1: purified
urease B; 2: protein marker. (B and C) The gels were transferred to
nitrocellulose membranes and probed with diluted human sera
(1:50) from a normal donor or an H. pylori-infected patient.
Detection was performed with a goat anti-human antibody linked
to HRP (1:10,000), followed by staining with 3-amino-9-
ethylcarbozole. 1: GST; 2: urease B; 3: protein marker.
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Figure 3 Inhibition of urease B enzymatic activity by specific
mAb U001. Urease (25 μl) was incubated with 25 μl mAb U001 or
U002 (equivalent to 0-25 μg) in 96-well microtitre plates overnight
at 4°C, with PBS as a control. On the following day, 50 μl5 0m M
phosphate buffer (pH 6.8) that contained 500 mM urea, 0.02%
phenol red, and 0.1 mM DTT was added to each well. The colour
development was monitored at 550 nm with a microplate reader.
The inhibition ratio was determined by the following equation:
[(activity without Ab - activity with Ab)/(activity without Ab)] × 100.
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intraperitoneal injection. Western blot analysis con-
firmed urease B recognition by the antisera (raised by
phage clones and the controls; Figure 7). The sera from
clone D1 (lane 1) and clone H1 (lane 2) reacted specifi-
cally with urease B protein at ~92 kDa, whereas the
pre-immune serum (lane 3), and the serum induced by
wild-type M13 phage (lane 4) or TBS (lane 5) were
negative. Triplicate ELISA measurements demonstrated
significant serum responses against urease B for each
sample and specific antibody responses from clone D1
and H1 were higher than others. The immune response
to wild-type M13 phage control was very low (Figure 8).
Alignment results from MIMOX
Computer-based analysis was performed to define the
consensus amino acid residues of the mimotopes.
Mimox wrapped ClustalW to align a set of mimotope
sequences that were analysed using an embedded ver-
sion of JalView. Figure 9 shows the resultant analysis,
which identified E, H, D and M as the consensus amino
acid residues in the aligned mimotopes.
Discussion
Investigators have demonstrated previously that peptide
mimotopes obtained from phage epitope libraries or by
chemical synthesis can bind antibodies raised against
native structures. In fact, peptide mimotopes have been
found for most, if not all, anti-carbohydrate mAbs [16].
Moreover, peptide epitopes can mimic glycosphingoli-
pids and oligonucleotide structures [15,25]. In the case
of mimotope immunisation, several studies have shown
effective responses in vivo [26,27]. Furthermore, protec-
tive immune responses by mimotope immunisation have
been verified in many infectious diseases [7,28-30].
In the field of vaccine design, the phage-displayed
mimotopes have recently been shown to be possible vac-
cine components that do not necessarily represent the
structural equivalents of the original antigen, but provide
functional images that could replace the original epitopes
Table 1 Enrichment of phage displaying epitope by panning over mAb U001 from ph.D.-12 and Ph.D.-C7C
Library Cycle coating mAb (mg/L) Washing (TBST) Input phage (pfu) Output phage (pfu) Recovery rate (%)
I 100 0.1% 1.5 × 10
11 8.4 × 10
3 5.6 × 10
-6
Ph.D.-12 II 10 0.3% 1.5 × 10
11 8.0 × 10
4 5.3 × 10
-5
III 1 0.5% 1.5 × 10
11 3.0 × 10
5 2.0 × 10
-4
I 100 0.1% 1.5 × 10
11 7.6 × 10
3 5.4 × 10
-6
Ph.D.-C7C II 10 0.3% 1.5 × 10
11 7.2 × 10
4 4.8 × 10
-5
III 1 0.5% 1.5 × 10
11 3.5 × 10
5 2.3 × 10
-4
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Figure 4 Binding specificity of selected phage from the Ph.D.-12 library. Wells of 96-well microtitre plates were coated with mAb U001 and
BSA (10 μg/ml, 100 μl) by incubation at 4°C overnight and blocked with 5% BSA in TBS. Affinity-selected phage were added to the wells and
allowed to bind at 37°C for 1 h. After the unbounded phage was removed, the bound phage was detected by incubation with peroxidase-
labelled murine anti-M13 antibodies. The bound peroxidase was determined by incubation with O-phenylenediamine dihydrochloride and the
reaction was determined in an ELISA reader at OD492. All the assays were carried out in triplicate and the error bars indicate standard deviation.
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Page 4 of 12for vaccine development [31-33]. Application of phage dis-
play technology to elucidate the essential chemical features
of conformational or discontinuous epitopes that are
recognised by some disease-related antibodies can provide
important information about the molecular mechanisms
of these diseases. The selected sets of peptides might also
lead to the future design of more effective reagents for
therapeutic and/or diagnostic purposes. The main advan-
tage of the phage-based approach is that it does not pro-
duce a consensus sequence of a large pool of peptides that
share a common property, but rather yields a list of pep-
tide sequences, each of which is endowed with the same
property. Alignment and comparison of the amino acid
sequences of the selected clones can then determine one
or more consensus sequences. This approach enabled us
to obtain the epitope profile of H. pylori in an efficient
manner. The profiles not only reveal the important roles
of each antigen, but also provide the epitope structures
within the antigenic protein that is involved in the induc-
tion of successful immune responses.
In this study, we first cloned and expressed urease B
of H. pylori,w h i c hw a st h e nu s e da sa ni m m u n o g e nt o
produce mAbs against this recombinant antigen by
hybridoma technology. We obtained two types of mAb
against different epitopes of urease B and observed that
mAb U001 strongly inhibited its enzymatic activity,
whereas mAb U002 did not induce this inhibitory activ-
ity. Therefore, mAb U001 could be beneficial for the
prevention of bacterial growth and attachment to the
gastric mucosa, thus, we identified the neutralising epi-
tope of this mAb via two phage display libraries (Ph.D.-
12 and Ph.D.-C7C). The two mimotopes of urease B
were characterised via affinity screening, binding, com-
petitive inhibition and DNA sequencing. Most clones
from the Ph.D.-12 library share the core EXXXHDM
sequence, therefore, we consider that EXXXHDM might
be a motif of urease B because clone D1 (with this
sequence) competitively inhibited U001 binding to
urease B and induced an immune response in mice.
Clone H1 (EKLKHSM sequence) from the Ph.D.-C7C
library appeared at a high frequency and had the same
function as clone D1. The mimotopes EXXXHDM and
EXXXHSM, which are highly homologous with urease B
residues 347-353 aa are also adjacent to a neutralising
epitope on urease B (321-339 aa), as reported previously
[34]. Li et al. have identified a B-cell-neutralising
￿
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Figure 5 Binding specificity of selected phage from the Ph.D.-C7C library. Wells of 96-well microtitre plates were coated with mAb U001
and BSA (10 μg/ml, 100 μl) by incubation at 4°C overnight and blocked with 5% BSA in TBS. Affinity-selected phage were added to the wells
and allowed to bind at 37°C for 1 h. After the unbounded phage was removed, the bound phage was detected by incubation with peroxidase-
labelled murine anti-M13 antibodies. The bound peroxidase was determined by incubation with O-phenylenediamine dihydrochloride and the
reaction was determined in an ELISA reader at OD492. All the assays were carried out in triplicate and the error bars indicate standard deviation.
Table 2 The sequences of ph.D.-12 and ph.D.-C7C phage-
displaying peptides from the recombinant phage clones
randomly selected through biopanning
Library Clone no. Sequence
UreaseB protein E DTLHDMGIFSI
(347-358)
D1~D3, D5,D6,D8,D9,
D11,D13
E HWSHDMFSPGD
D10,D15 E VSLHDMNLATH
Ph.D.-12 D4 K W L G HDMIMSGT
D7 F N T K HDMQGDTS
D12 E HNDFPM YTWRP
D 1 4 TTTHFLATKFYK
H1~H2, H4,H6~H9,H11,
H13,H15
E KLKHSM
H5,H10 T K T W Q SM
Ph.D.-C7C H 3 MSLLGHK
H12 K H G L L S M
H14 M S Q D G H T
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Page 5 of 12epitope of urease B (211-225 aa) [35]. These observa-
tions suggest that there are predominant antigenic epi-
topes on the urease B protein that are effectively
targeted.
The mimotopes selected from the above-mentioned
phage display libraries are not completely homologous
with the known amino acid sequence of urease B. Many
researchers have demonstrated similar results to ours
using antibodies as a tool to screen phage display library
mimotopes for other target protein antigens. One reason
for the disparity in mimotope urease B sequences might
be that the epitopes that are recognised by the gener-
ated mAbs could be a linear or conformational epitope
that consists of a discontinuous amino acid sequence. In
the latter case, the discontinuous amino acids could be
in close spatial proximity due to the folding of peptides.
We therefore speculate that amino acids E, D, H, M and
S are key residues for the urease B epitope. Our results
suggest that sequences that contain EXXXHDM and
EXXXHSM with potential antigenicity and immunogeni-
city should be further studied for their use in the devel-
opment of a diagnostic reagent, and vaccine that targets
H. pylori urease B. It is particularly interesting that H3
and H12 screened from the Ph.D.-C7C library (Table 2)
are exactly the same but in inverse order. Unlike the Ph.
D.-12 phage display library, the randomised sequence of
the Ph.D-C7C library is flanked by a pair of cysteine
Figure 7 Western blot analysis of antiserum induced by
phagotopes. Two phage (clones D1 and H1) were used to
immunise BALB/c mice through intraperitoneal administration. For
each immunisation, 10
12 pfu phage (in 50 μl) was used, with TBS
and wild-type M13 phage as controls. Three mice were immunised
with each sample and pre-immune sera were obtained. The mice
were bled once (pre-booster), and they were given a booster in the
same manner. The immune mice were bled every 7 days after
booster immunisation, and western blotting was performed to test
each serum sample. 1: serum from D1 phagotope; 2: serum from H1
phagotope; 3: pre-immune serum; 4: serum from wild M13phage; 5:
serum from TBS.
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Figure 6 Phage inhibition of mAb U001 binding to urease B protein. Wells of microtitre plates were coated with urease B protein and
incubated with the mAb U001 (0.5 μg) plus increasing amounts (10
9-10
15 pfu) of the selected phage (clones D1 and H1). The binding was
monitored by OD492 measurements after reaction with the peroxidase-conjugated goat anti-mouse IgG. The inhibition ratio was determined by
the following equation: [(activity without Ab - activity with Ab)/(activity without Ab)] × 100.
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Page 6 of 12residues. Under non-reducing conditions, the cysteine
residues spontaneously form a disulfide cross-link,
which results in phage display of cyclized peptides. Dis-
ulphide-constrained peptide libraries have previously
proven useful in identification of structural epitopes.
From this study, we presume that the epitope recog-
nised by mAb U001 is a structural epitope. Amio acid S
and M, which are also included in H1, are the key
amino acids that constitute this structural epitope.
Although the immune systems in mice and humans
differ, it is still informative to check the immune
responses and evaluate the potential of these experimen-
tal vaccine candidates in mice. Recombinant phage can
display epitopes and also bear significant adjuvant activ-
ity [36], therefore, we directly used phagotopes as anti-
gens to immunise mice. Our findings showed that the
phage-displayed epitope was able to mimic immunologi-
cal properties of the native epitope on H. pylori urease
B. Furthermore, using phage-displayed epitopes as anti-
g e n s ,w ew e r ea b l et od e t e c tt h ea n t i b o d yi nt h es e r a
from immunised animals. The results suggest that the
phagotopes also provide a convenient and economic
approach to prepare antigens, and could be applied in
an ELISA-based method for the rapid diagnosis of
H. pylori infection.
Conclusions
We demonstrated the feasibility of identifying important
mimotopes of urease B for vaccine development by
screening phage-displayed random peptide libraries with
mAb. The results also indicate the potential application
of phagotopes as alternative vaccine components. Com-
parison of mimotopes selected from a peptide library
with mAb and the original antigen sequence could lead
to a better understanding of the molecular mechanisms
that participate in the immune response and to the
design of specific peptides for diagnostic purposes and
vaccine development.
Methods
Bacterial strains and growth conditions
H. pylori strain NCTC11639 was obtained from the
Department of Microbiology, Southern Medical Uni-
versity (Guangzhou, China). This cell line was routi-
nely cultured on Columbia agar plates supplemented
with 7% saponin-lysed horse blood, 0.004% triphenyl-
tertrazolium chloride, and Dent selective supplement
(Oxoid, Basingstoke, UK) for 3 days at 37°C under a
micoaerophilic atmosphere (5% O2,15% CO2 and
80% N2). A colony was picked up and inoculated into
20 ml Brucella broth (Becton Dickinson, Cockeysville,
M D ,U S A )t h a tc o n t a i n e d0 . 1 %b-cyclodextrin supple-
mented with 5% (v/v) horse serum for 24 h. Two milli-
litres of culture medium was transferred to 40 ml fresh
medium and the same processes were repeated twice.
One millilitre of the incubated cell-containing medium
(mostly spiral rather than coccoid bacteria) was plated
on Brucella agar (Becton Dickinson) that contained 7%
(v/v) defibrinated horse blood, and cultured for an
additional 3 days at 37°C in a microaerophilic atmo-
sphere. Bacterial cells were harvested and washed
twice with cold PBS (25 mM sodium phosphate, pH
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Figure 8 Serum antibodies induced by phagotopes. Two purified phage clones (D1 and H1) were used to immunise BALB/c mice through
intraperitoneal administration. For each immunisation, phage (10
12 pfu/50 μl) were used, with TBS and wild-type M13 phage as controls. Three
mice were immunised with each sample and pre-immune sera were obtained. The mice were bled once (pre-booster), and they were given a
booster in the same manner. The immune mice were bled every 7 days after the booster immunisation, and triplicate ELISAs were performed to
test each serum sample with urease B as coated protein. All assays were carried out in triplicate and the error bars indicate standard deviation.
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Page 7 of 127.2, 0.9% NaCl, pH 7.0). The cells were sedimented by
centrifugation (5,000×g for 10 min at 4°C) and stored
at -80°C.
Cloning, expression and enzymatic activity of
recombinant urease B protein
Genomic H. pylori DNA was prepared using a DNA
extraction kit (Takara, Belmont, Japan) according to the
manufacturer’s instructions. Extracted genomic DNA
was then used as the template for amplification of the
urease B coding region using the Taq DNA polymerase
PCR kit (Takara). Two primer sequences that corre-
sponded to the 5’ and 3’ end of coding gene plus
EcoRI and SalI restriction sites were P1: 5’-TGCGAA
TTCAAAAAGATTAGCAGAAAA-3’ and P2: 5’-GG
GTCGACGAAAATGCTAAAGAGTTG-3’.T h eP C R
products were cloned into an EcoRI- and SalI-digested
pGEX-4T-1 expression vector (Amersham Biosciences).
The plasmid was then transformed into E. coli strain
TOP10 (Invitrogen BV, Leek, The Netherlands) and
urease B expression was induced with 1 mM IPTG
when the cells were in log phase growth at 37°C. After
4 h, the cells were harvested by centrifugation at 7000
rpm/min for 10 min and washed with ice-cold PBS that
contained 5 mM EDTA and 2 mM PMSF. All subse-
quent procedures were performed at 4°C.
To purify recombinant urease B, the cells were resus-
pended in PBS that contained 5 mM EDTA and 2 mM
PMSF and lysed by sonication on ice, and centrifuged
at 10,000 rpm for 20 min to sediment cell debris. The
supernatant was applied to Glutathione Sepharose 4B
(Pharmacia, Uppsala, Sweden) to purify urease B
A A B A
D C
Figure 9 Mimotopes selected out with U001 were input and aligned with ClustalW. (A) Alignment of multiple sequences by ClustalW.
(B) The frequency of a given amino acid at each position of the alignment was calculated and displayed in a table. (C) A 3D bar figure was
created. The x axis represents the 20 amino acid types and gap, whereas the y axis is the frequency of occurrence and the z axis is the position
of the aligned sequences. (D) The alignment could be managed with JalView.
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Page 8 of 12protein according to the manufacturer’sp r o t o c o l .
Urease B samples were analysed by electrophoresis on
a 10% SDS-polyacrylamide gel. The gels were stained
for protein with 0.25% Coomassie Blue or transferred
to a nitrocellulose membrane (Millipore, Bedford, MA,
USA) and probed with diluted human sera (1:50 dilu-
tion with PBS) from a patient diagnosed with H. pylori
infection (positive serum) and a normal donor without
infection (negative serum). Detection was performed
with a goat anti-human antibody linked to horseradish
peroxidase (1:10,000) followed by staining with
3-amino-9-ethylcarbozole (Sigma, St Louis, MO, USA)
as a chromogen.
Production of the mAb and urease B inhibition test
BALB/c female mice, 4-6 weeks old, were purchased
from the Animal Center of Southern Medical University.
The mice were immunised by intraperitoneal injection
with 50 μg purified urease B-GST, which was emulsified
with an equal volume of Freund’s complete adjuvant.
Three additional booster injections were administered
using incomplete adjuvant every 2 weeks. Three days
after the last injection, the spleen cells were harvested
and fused with the Sp 2/0 mouse myeloma cell line.
After 10-14 days, the culture supernatants were
screened for positive mAbs against recombinant urease
B-GST by ELISA. In the screening process, the mAbs
that reacted with urease B-GST but not with GST were
selected. Positive colonies were subcloned twice by lim-
iting dilution. Ascitic fluid was obtained from mice
primed with a 0.5-ml intraperitoneal injection of Pris-
tane and then injected with 10
6 hybridoma cells. The
class and subclass of each mAb were determined with a
mouse monoclonal antibody isotyping kit (HyCult Bio-
technology, Uden, The Netherlands). The mAbs were
purified using protein G-Sepharose 4FF (Pharmacia)
according to the manufacturer’s instructions, to remove
components that might have interfered with the biopan-
ning experiments.
T h ea n t i b o d yt i t r e sw e r ed e t e r m i n e db yE L I S A .P u r i -
fied urease B-GST antigen was coated on the microti-
tre plates (100 μl/well, 5 μg/ml in coating solution, 0.1
M sodium bicarbonate, pH 9.6) (Corning, Corning,
NY, USA) and incubated at 4°C overnight. The super-
natants of the cell culture as well as the ascitic fluids
were incubated with pre-coated urease B-GST (100 μl/
well) for 2 h at 37°C. Goat anti-mouse IgG HRP
(1:10,000 dilution with washing buffer) was used to
detect urease B-GST mAbs and O-phenylenediamine
dihydrochloride (Pierce Chemicals) was used as sub-
strate for HRP and the reaction was monitored at an
absorption of 492 nm using a microplate reader
(Model 550; Bio-Rad).
The affinity constant (Ka) of mAbs was determined by
using a method that was developed by Beatty [37].
Urease B-GST protein was coated on the ELISA plates
at three different concentrations ([Ag], [Ag’], and [Ag’’])
followed by incubation with each mAb at different
concentrations. The Ka of each mAb was calculated
based upon the sigmoid curves that represented the
relationship between the concentration of mAb and the
OD values. The antibody concentration at half maximal
absorption for each curve was obtained by extrapolating
the curves and named ([Ab], [Ab’], and [Ab’’]). The Ka
was calculated using the following equation: K = (n-1)/2
(n [Ab’] -[Ab]), where n = Ag/Ag’.
Using competitive ELISA, the topology of the epitopes
that were recognised by the mAbs was studied. Competi-
tive tests compared the ability of the various unlabeled
mAbs (competitors) to compete with the peroxidase-
conjugated mAbs for binding to urease B that was immo-
bilised on ELISA plates, in which saturating amounts of
unlabelled mAbs were added to the plates coated with
urease B protein before addition of labelled mAbs. Differ-
ent concentrations of each competitor mAb in PBS,
which contained a constant concentration of a labelled
mAb, were co-incubated with immobilised urease B for
40 min at 37°C. Following extensive washing with PBS,
the plates were developed with O-phenylenediamine
dihydrochloride (Pierce Chemicals) as mentioned above.
Percentage inhibition was finally estimated based on the
following calculation: percentage inhibition = [(OD with-
out competitor) - (OD with competitor)/OD without
competitor] ×100.
Purified H. pylori urease B was prepared. Stored cell
pellets were thawed, resuspended in 10% n-octyl b-D-
glucopyranoside (Wako Pure Chemical Industries),
vortexed five times for 10 s each, and centrifuged at
10,000 × g for 20 min at 4°C). DL-Dithiothreitol (DTT;
0.1 mM) (Sigma) was added to the supernatant, and the
mixture was applied to a PD-10 column (Sephadex G-25;
Pharmacia Biotech, Uppsala, Sweden), and the eluate was
dialysed against PBS that contained DTT. The eluate was
applied to a column (Shoei Works Co.) with Affi-Gel Hz
hydrazide gel (Bio-Rad) coupled to D12(S3) overnight in
a cold room. The column was washed with PBS that con-
tained DTT, and elution was performed with 5 M urea in
0.1 M potassium phosphate buffer (pH 6.5) that con-
tained 0.1 mM DTT. The eluate was dialysed with the
PD-10 column. The amount of protein was determined
by Lowry’s method.
The H. pylori urease inhibition test was carried out
using the mAbs prepared above. Urease (25 μl) was
incubated with 25 μl anti-urease B epitope mAb U001,
U002 (equivalent to 0-25 μg) in 96-well microtitre plates
overnight at 4°C, with PBS as the control. On the
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that contained 500 mM urea, 0.02% phenol red, and 0.1
mM DTT was added to each well. The colour develop-
ment was monitored at 550 nm with a microplate
reader (Model 550; Bio-Rad). Percentage inhibition was
determined by the following equation: [(activity without
Ab - activity with Ab)/(activity without Ab)] × 100.
Phage display library screening using specific mAb as a
target molecule
The Ph.D.-12 and Ph.D.-C7C libraries were obtained
from New England BioLabs. They were combinatorial
peptides that were fused to the minor coat protein (pIII)
of M13 phage, and consisted of about 1.5×10
13 and
2×10
13 pfu/ml electroporated sequences, respectively.
Three rounds of biopanning were undertaken according
to the manufacturer’s instructions, with some modifica-
tions. A plate well was coated with 100 μg/well of anti-
urease B mAb U001 in 0.1 M NaHCO3,p H8 . 6 ,a n d
incubated overnight at 4°C. The well was washed 10
times with TBST (50 mM Tris, 150 mM NaCl, pH 7.5,
and 0.1% Tween-20), filled with 400 μl blocking buffer
(0.1 M NaHCO3, pH 8.6, 5 mg/ml BSA, and 0.02%
NaN3) ,a n di n c u b a t e df o r1ha t4 ° C .I nt h ef i r s tr o u n d
of biopanning, 10 μlp h a g e( 1 . 5 × 1 0
11) from the initial
library, in 100 μl TBST, was incubated with the well-
bound mAb for 1 h at room temperature, under rocking
conditions. After repeated washes with TBST, the
bound phage was eluted from the well with 100 μle l u -
tion buffer (0.2 M glycine-HCl, pH 2.2). After neutrali-
sation with 15 μl 1 M Tris-HCl, pH 9.1, the eluted
phage were amplified by infecting 20 ml of a 1:100 dilu-
tion of an overnight culture of E. coli ER2738. The cul-
ture was incubated for 4.5 h at 37°C with vigorous
shaking. The supernatants were obtained and precipi-
tated with PEG/NaCl.
In the second and third rounds of biopanning, 20% of
the amplified phage from the preceding round was incu-
bated with mAb U001 overnight at 4°C as described
above. The procedures were identical to the first round
except that the coated mAb concentration was 10 mg/l
and 1 mg/l, and the washing steps were carried out with
0.3% and 0.5% TBST for the second and third round of
biopanning, respectively.
Binding specificity of the selected phage by ELISA and
DNA sequencing
Ninety-six-well plates were coated with mAb U001 and
BSA (10 μg/ml, 100 μl) by incubation at 4°C overnight,
and blocked with 5% BSA in TBS. Affinity-selected phage
were added to the wells and allowed to bind at 37°C for
1h .A f t e rt h eu n b o u n d e dp h a g ew a sr e m o v e dw i t h5 %
TBST, the bound phage were detected by incubation
with peroxidase-labelled murine anti-M13 antibodies
( P r o m e g a ,M a d i s o n ,W I ,U S A ) .T h eb o u n dp e r o x i d a s e
was determined by incubation with O-phenylenediamine
dihydrochloride (Pierce Chemicals) in buffer (30 mM
citrate, 70 mM Na2HPO4, and 0.02% H2O2,p H5 . 5 ) .
After the reaction was stopped by the addition of 3 N
HCl, A492 was determined with an ELISA reader (model
550; Bio Rad). All the assays were carried out in triplicate.
The phage from the third biopanning eluate were
cloned and amplified for DNA sequencing and immu-
noanalysis. The nucleotide sequence of the gene III
insert was determined as per the instruction manual.
The amino acid sequence of the insert was deduced
f r o mt h en u c l e o t i d es e q u e n c ea n dw a sc o m p a r e dw i t h
native urease B sequence using DNAMAN version 6.0
software. The sequences that appeared >3 times among
the selected phage clones were classified as the consen-
sus sequence. The aligned amino acid sequences shared
by three (or more) identical amino acids within the
dodecapeptides (heptapeptides) were determined as the
mimotopes of the matched protein sequences.
Competitive ELISA analysed the binding specificities
of the recombinant phage to the screened mAb U001.
The wells of microtitre plates were coated with urease B
protein and incubated with mAb U001 (0.5 μg) plus
increasing amounts of the selected phage. The binding
was monitored by OD492 measurements after reaction
with the peroxidase-conjugated goat anti-mouse IgG
(Sigma).
Animal immunisation and preparation of antisera
To evaluate the potential of the selected mimotopes as
experimental vaccine candidates, two purified phage
clones (D1 and H1) were used to immunise female
inbred specific-pathogen-free BALB/c mice through
intraperitoneal administration. For each immunisation,
phage (~10
12 pfu/50 μl) was used, and TBS and wild-
type M13 phage were used as the negative controls.
Three mice were immunised with each sample and pre-
immune sera (negative control) were obtained. The
mice were bled once (pre-booster), and then they were
given booster injections in the same manner. The
immune mice were bled every 7 days after the booster
immunisation, and ELISA and western blotting were
performed to test each serum sample for H. pylori
urease B-specific antibody activity.
Analyzing mimotopes with MIMOX
MIMOX (http://immunet.cn/mimox/intro.html#7) is a
web tool for bioinformatics analysis of peptide
sequences derived from phage display. The interface
ClustalW can align a set of mimotope sequences and
deduce consensus sequences based on the aligned
mimotopes through a simple statistical method. A set of
mimotopes obtained above (including 6 dodecapeptides
Li et al. BMC Biotechnology 2010, 10:84
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Page 10 of 12and 5 heptapeptides) was input and aligned with all
parameters as defaults. The alignment can be viewed
and managed through JAIView.
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